Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor

Jamie L. Rogers, Liela Bayeh, Thomas H. Scheuermann, Jamie Longgood, Jason Key, Jacinth Naidoo, Lisa Melito, Cameron Shokri, Doug E. Frantz, Richard K. Bruick, Kevin H. Gardner, John B. MacMillan, Uttam K. Tambar

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Hypoxia inducible factors (HIFs) are heterodimeric transcription factors induced in a variety of pathophysiological settings, including cancer. We describe the first detailed structure-activity relationship study of small molecules designed to inhibit HIF-2α-ARNT heterodimerization by binding an internal cavity of the HIF-2α PAS-B domain. Through a series of biophysical characterizations of inhibitor-protein interactions (NMR and X-ray crystallography), we have established the structural requirements for artificial inhibitors of the HIF-2α-ARNT PAS-B interaction. These results may serve as a foundation for discovering therapeutic agents that function by a novel mode of action.

Original languageEnglish (US)
Pages (from-to)1739-1747
Number of pages9
JournalJournal of Medicinal Chemistry
Volume56
Issue number4
DOIs
StatePublished - 2013

Fingerprint

Transcription Factors
X Ray Crystallography
Structure-Activity Relationship
endothelial PAS domain-containing protein 1
Neoplasms
Proteins
Therapeutics
Hypoxia

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Rogers, J. L., Bayeh, L., Scheuermann, T. H., Longgood, J., Key, J., Naidoo, J., ... Tambar, U. K. (2013). Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor. Journal of Medicinal Chemistry, 56(4), 1739-1747. https://doi.org/10.1021/jm301847z

Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor. / Rogers, Jamie L.; Bayeh, Liela; Scheuermann, Thomas H.; Longgood, Jamie; Key, Jason; Naidoo, Jacinth; Melito, Lisa; Shokri, Cameron; Frantz, Doug E.; Bruick, Richard K.; Gardner, Kevin H.; MacMillan, John B.; Tambar, Uttam K.

In: Journal of Medicinal Chemistry, Vol. 56, No. 4, 2013, p. 1739-1747.

Research output: Contribution to journalArticle

Rogers, JL, Bayeh, L, Scheuermann, TH, Longgood, J, Key, J, Naidoo, J, Melito, L, Shokri, C, Frantz, DE, Bruick, RK, Gardner, KH, MacMillan, JB & Tambar, UK 2013, 'Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor', Journal of Medicinal Chemistry, vol. 56, no. 4, pp. 1739-1747. https://doi.org/10.1021/jm301847z
Rogers JL, Bayeh L, Scheuermann TH, Longgood J, Key J, Naidoo J et al. Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor. Journal of Medicinal Chemistry. 2013;56(4):1739-1747. https://doi.org/10.1021/jm301847z
Rogers, Jamie L. ; Bayeh, Liela ; Scheuermann, Thomas H. ; Longgood, Jamie ; Key, Jason ; Naidoo, Jacinth ; Melito, Lisa ; Shokri, Cameron ; Frantz, Doug E. ; Bruick, Richard K. ; Gardner, Kevin H. ; MacMillan, John B. ; Tambar, Uttam K. / Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor. In: Journal of Medicinal Chemistry. 2013 ; Vol. 56, No. 4. pp. 1739-1747.
@article{2cf3c2c0abf747c48ac7f7d89f42b3d5,
title = "Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor",
abstract = "Hypoxia inducible factors (HIFs) are heterodimeric transcription factors induced in a variety of pathophysiological settings, including cancer. We describe the first detailed structure-activity relationship study of small molecules designed to inhibit HIF-2α-ARNT heterodimerization by binding an internal cavity of the HIF-2α PAS-B domain. Through a series of biophysical characterizations of inhibitor-protein interactions (NMR and X-ray crystallography), we have established the structural requirements for artificial inhibitors of the HIF-2α-ARNT PAS-B interaction. These results may serve as a foundation for discovering therapeutic agents that function by a novel mode of action.",
author = "Rogers, {Jamie L.} and Liela Bayeh and Scheuermann, {Thomas H.} and Jamie Longgood and Jason Key and Jacinth Naidoo and Lisa Melito and Cameron Shokri and Frantz, {Doug E.} and Bruick, {Richard K.} and Gardner, {Kevin H.} and MacMillan, {John B.} and Tambar, {Uttam K.}",
year = "2013",
doi = "10.1021/jm301847z",
language = "English (US)",
volume = "56",
pages = "1739--1747",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor

AU - Rogers, Jamie L.

AU - Bayeh, Liela

AU - Scheuermann, Thomas H.

AU - Longgood, Jamie

AU - Key, Jason

AU - Naidoo, Jacinth

AU - Melito, Lisa

AU - Shokri, Cameron

AU - Frantz, Doug E.

AU - Bruick, Richard K.

AU - Gardner, Kevin H.

AU - MacMillan, John B.

AU - Tambar, Uttam K.

PY - 2013

Y1 - 2013

N2 - Hypoxia inducible factors (HIFs) are heterodimeric transcription factors induced in a variety of pathophysiological settings, including cancer. We describe the first detailed structure-activity relationship study of small molecules designed to inhibit HIF-2α-ARNT heterodimerization by binding an internal cavity of the HIF-2α PAS-B domain. Through a series of biophysical characterizations of inhibitor-protein interactions (NMR and X-ray crystallography), we have established the structural requirements for artificial inhibitors of the HIF-2α-ARNT PAS-B interaction. These results may serve as a foundation for discovering therapeutic agents that function by a novel mode of action.

AB - Hypoxia inducible factors (HIFs) are heterodimeric transcription factors induced in a variety of pathophysiological settings, including cancer. We describe the first detailed structure-activity relationship study of small molecules designed to inhibit HIF-2α-ARNT heterodimerization by binding an internal cavity of the HIF-2α PAS-B domain. Through a series of biophysical characterizations of inhibitor-protein interactions (NMR and X-ray crystallography), we have established the structural requirements for artificial inhibitors of the HIF-2α-ARNT PAS-B interaction. These results may serve as a foundation for discovering therapeutic agents that function by a novel mode of action.

UR - http://www.scopus.com/inward/record.url?scp=84874605449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874605449&partnerID=8YFLogxK

U2 - 10.1021/jm301847z

DO - 10.1021/jm301847z

M3 - Article

VL - 56

SP - 1739

EP - 1747

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 4

ER -